2020 Annual Meeting Invited Program Plus Oral
Description
As the premier event in malignant and non-malignant hematology, the ASH annual meeting provides attendees with an outstanding educational experience that examines the latest clinical advances in hematology and explores the year's most significant scientific discoveries and updates. The videos make this event available for convenient, on-demand viewing.
ASH offers four package options, where you can choose between scientific and educational content, purchase both at a lower price, or purchase the complete meeting including oral abstracts.
The 2020 ASH Annual Meeting Scientific Program package includes all of the following sessions:
• General Sessions
• Scientific Program Sessions
• Special Scientific Symposia
• Special-Interest Sessions
• Spotlight Sessions
• Trainee Simultaneous Didactic Sessions
Access the 2020 ASH Annual Meeting – Invited plus Oral Abstracts for all webcast sessions.
ASH offers four package options, where you can choose between scientific and educational content, purchase both at a lower price, or purchase the complete meeting including oral abstracts.
The 2020 ASH Annual Meeting Scientific Program package includes all of the following sessions:
• General Sessions
• Scientific Program Sessions
• Special Scientific Symposia
• Special-Interest Sessions
• Spotlight Sessions
• Trainee Simultaneous Didactic Sessions
Access the 2020 ASH Annual Meeting – Invited plus Oral Abstracts for all webcast sessions.
Pricing
This meeting is currently not available for purchase.
Sessions
This item is a pre-sale item. The sessions are not live yet. Once you purchase, the sessions will automatically be available to you when the sessions go live.
Complete Meeting
Education Program
- A Map for the Changing Landscape of CLL
- Acute Myeloid Leukemia - So Many Treatment Options; How Do You Decide?
- Advances in the Laboratory Assessment of Hemostatic and Thrombotic Disorders
- Aggressive Lymphomas: What Novel Approaches Are Ready for Prime Time?
- Anxiety Provoking Hematology Consults, Second Edition
- Beyond the Marrow: Major Non-Hematologic Complications of Inherited Bone Marrow Failure Syndromes
- Caring for Patients with Acute Leukemia in Community Hospitals: Who, What, and When to Refer?
- Challenging Situations for Patients with Aggressive Lymphomas
- Chronic Transfusion Support: Challenging Cases
- Diagnostic and Prognostic Models in VTE Management: Ready for Primetime?
- Genetic Testing for Heritable Hematologic Disorders 101
- Handling Challenging Questions in the Management of CML
- Immunotherapy in Multiple Myeloma
- Improving Symptom Control for Children with Hematological Malignancies
- Indolent Lymphomas: Answers to Smoldering Questions
- Infection Risk, Immunization Recommendations, and Antimicrobial Prophylaxis Needs when Treating Non-Malignant Hematologic Disorders - Wash Your Hands and What Else?
- Junior Faculty Career Development Education Session
- Managing Toxicities of Targeted Therapies in CLL
- Monoclonal Gammopathies of Determined Significance
- Myelodysplastic Syndromes: What We Have and What We Want
- Myeloproliferative Disorders: Too Many Cells, Too Few Therapies - How Do We Choose?
- Out of Balance: Anemias Due to Disordered Iron Homeostasis
- Pediatric Hematological Malignancies: CARs for Kids
- Platelet Transfusions for Hematology / Oncology Patients: Taking a More Granular Look
- Selected Hemostasis and Thrombosis Topics in Women
- The Brain and Pain in Sickle Cell Disease: Understanding the Role of Sensory, Cognition and Neuropathic Pathways in the SCD Chronic Pain Experience
- The Emerging Role of Targeted Therapies and Cell Therapy in Transplant
- Understanding How to Manipulate the Immune System in Immunotherapy for Lymphoma
- Updates on the Role of Non-Anticoagulant Interventions in Venous Thromboembolism
- What Hematologists Need to Know About Giving and Stopping Aspirin
- Yin and Yang of Autoimmunity and Immunodeficiencies in Hematology
General Sessions
- ASH Awards Presentation
- ASH-EHA Joint Symposium: Failure of Targeted Cellular Immunotherapy and Hematopoietic Cell Transplant: Mechanisms and Mitigating Strategies
- Best of ASH
- Business Meeting
- E. Donnall Thomas Lecture and Prize
- Ernest Beutler Lecture and Prize
- Fireside Chat with Dr. Anthony Fauci
- Ham-Wasserman Lecture
- Late-Breaking Abstracts Session
- Plenary Scientific Session
- Presidential Symposium: Universal Donor Solutions in Hematology
Oral and Poster Abstracts
- 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Mechanisms and Regulation of Erythropoiesis
- 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Mechanisms, Diagnosis and Treatment of Inherited
- 102. Regulation of Iron Metabolism
- 112. Thalassemia and Globin Gene Regulation
- 113. Hemoglobinopathies, Excluding Thalassemia�New Genetic Approaches to Sickle Cell Disease: Fetal Hemoglobin Regulation And Reticulocyte Maturation In Sickle Cell Disease
- 113. Hemoglobinopathies, Excluding Thalassemia�New Genetic Approaches to Sickle Cell Disease: New Insights Into Sickle Cell Disease Pathophysiology
- 114. Hemoglobinopathies, Excluding Thalassemia�Clinical: Assessment and Prevention of End-Organ Injury in Sickle Cell Disease
- 114. Hemoglobinopathies, Excluding Thalassemia�Clinical: Hydroxyurea for Sickle Cell Disease: Treatment Benefits and Potential Reproductive Risks for Women
- 114. Hemoglobinopathies, Excluding Thalassemia�Clinical:Novel Treatments for Sickle Cell Disease
- 201. Granulocytes, Monocytes, and Macrophages
- 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Hematologic Malignancies and COVID-19
- 203. Lymphocytes, Lymphocyte Activation, and Immunodeficiency, including HIV and Other Infections: Pathogenesis and Immunotherapy
- 301. Vascular Wall Biology, Endothelial Progenitor Cells, and Platelet Adhesion, Activation, and Biochemistry
- 311. Disorders of Platelet Number or Function: Heparin-Induced Thrombocytopenia and Immune Thrombocytopenia
- 311. Disorders of Platelet Number or Function: Thrombotic Thrombocytopenic Purpura and Platelet Dysfunction
- 321. Blood Coagulation and Fibrinolytic Factors: Coagulation and Fibrinolytic Factors: Regulation of Coagulation
- 322. Disorders of Coagulation or Fibrinolysis: Hemophilia: Genes, Joints, and PK
- 322. Disorders of Coagulation or Fibrinolysis: Hemophilia: Treatment and Inhibitors
- 322. Disorders of Coagulation or Fibrinolysis: Von Willebrand Disease and Bleeding
- 331. Pathophysiology of Thrombosis I
- 331. Pathophysiology of Thrombosis II
- 332. Anticoagulation and Antithrombotic Therapy: COVID-19, Obesity and Hemorrhagic Complications
- 332. Anticoagulation and Antithrombotic Therapy: Novel Agents, Reversal Drugs and Indications
- 401 Basic Science and Clinical Practice in Blood Transfusion: COVID-19 Convalescent Plasma and Transfusion Immunology I
- 401 Basic Science and Clinical Practice in Blood Transfusion: COVID-19 Convalescent Plasma, Antigen Typing and the Prothrombin Complex II
- 501. Hematopoietic Stem and Progenitor Biology: New Insights into the Molecular Regulation of Hematopoietic Stem Cells
- 502. Hematopoiesis: Regulation of Gene Transcription, Cytokines, Signal Transduction, Apoptosis, and Cell Cycle Regulation: Molecular regulation of cell fate and regeneration
- 503. Clonal Hematopoiesis: Aging and Inflammation
- 506. Hematopoiesis and Stem Cells: Microenvironment, Cell Adhesion, and Stromal Stem Cells
- 508. Bone Marrow Failure: Advancing Our Biologic Understanding in Inherited and Acquired Bone Marrow Failure Disorders
- 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Aberrant Nuclear Architecture and Chromatin Remodeling
- 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Altered Transcription Factor Regulation
- 603. Oncogenes and Tumor suppressors: Pre clinical models and Novel Targets
- 604. Molecular Pharmacology and Drug Resistance in Myeloid Diseases
- 605. Molecular Pharmacology, Drug Resistance�Lymphoid and Other Diseases: Molecular pharmacology and drug resistance mechanisms in lymphoproliferative disorders
- 612. Acute Lymphoblastic Leukemia: Clinical Studies: Innovative Chemotherapy and Immunotherapy Strategies in Frontline and Relapsed Disease
- 612. Acute Lymphoblastic Leukemia: Clinical Studies: Insights in Genomics, MRD, and Toxicities
- 613. Acute Myeloid Leukemia: Molecular Mutations and Their Prognostic Implications
- 613. Acute Myeloid Leukemia: Novel Therapies and Treatment Approaches
- 613. Acute Myeloid Leukemia: Potpourri of Potential Practice Changing Studies
- 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Chimeric Antigen Receptor T Cell Therapy
- 614. Acute Lymphoblastic Leukemia: Therapy, excluding Transplantation: Targeted Therapies
- 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Commercially Available Therapy, excluding Transplantation I
- 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Commercially Available Therapy, excluding Transplantation II
- 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Advances in immunotherapeutics for management of AML
- 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel combination therapies in treatment of newly diagnosed AML
- 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Novel promising therapies for relapsed/refractory AML
- 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Dissecting AML heterogeneity to refine treatment approaches
- 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: MRD and Novel molecular Markers
- 617. Acute Myeloid Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis: Single Cell Profiling and Novel molecular Markers
- 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis I
- 618. Acute Lymphoblastic Leukemia: Biology, Cytogenetics, and Molecular Markers in Diagnosis and Prognosis II
- 621. Lymphoma�Genetic/Epigenetic Biology: Clinical implications of biological insights in lymphoma
- 621. Lymphoma�Genetic/Epigenetic Biology: Genetic and epigenetic profiling of malignant lymphomas
- 622. Lymphoma Biology�Non-Genetic Studies: Mechanisms of Lymphomagenesis, Progression, and Response
- 622. Lymphoma Biology�Non-Genetic Studies: Microenvironment and Immune Response in Hodgkin Lymphoma
- 623. Mantle Cell and Indolent B-Cell Lymphoma - CAR-T and immunotherapy clinical studies
- 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma�Clinical Studies: Clinical studies in Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma and Hairy Cell Leukemia
- 623. Mantle Cell, Follicular, and Other Indolent B-Cell Lymphoma�Clinical Studies: Mantle Cell Lymphoma Clinical Trials
- 624. Hodgkin Lymphoma and T/NK Cell Lymphoma�Clinical Studies: Clinical Studies in Hodgkin Lymphoma
- 624. Hodgkin Lymphoma and T/NK Cell Lymphoma�Clinical Studies: Clinical Studies in T/NK Cell Lymphoma
- 624. Hodgkin Lymphoma and T/NK Cell Lymphoma�Clinical Studies: Immunotherapy in T/NK Cell Lymphoma
- 625. Lymphoma: Pre-Clinical�Chemotherapy and Biologic Agents: Novel Approaches to Overcome Resistance
- 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)�Results from Prospective Clinical Trials: Incorporating novel agents and new adoptive cell therapy approaches
- 626. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)�Results from Prospective Clinical Trials: Updates and advances in bispecific antibody therapies and autologous CAR-T approaches
- 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)�Results from Retrospective/Observational Studies: Biomarkers and Prognostication in Aggressive B-Cell Non-Hodgkin Lymphomas
- 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)�Results from Retrospective/Observational Studies: Front-Line Treatment and Prognostication of Burkitt Lymphoma, Plasmablastic Lymphoma, and DLBCL
- 627. Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)�Results from Retrospective/Observational Studies: PCNSL Treatment and Prognosis and CNS Prophylaxis in High-Risk Aggressive Lymphomas
- 631. CML: Biology and Pathophysiology, excluding Therapy: Mechanisms of Resistance and Progression in CML
- 632. Chronic Myeloid Leukemia: Therapy� Building The Future CML
- 632: Chronic Myeloid Leukemia: Therapy: CML: New and Beyond
- 634. Myeloproliferative Syndromes: Clinical: Clinical Trials in Polycythemia Vera
- 634. Myeloproliferative Syndromes: Clinical: New Therapies and JAKi-based Combinations for Myelofibrosis
- 634. Myeloproliferative Syndromes: Clinical: Translational Science in MPN� Hitting the Mark
- 635. Myeloproliferative Syndromes: Basic Science
- 636. Myelodysplastic Syndromes � Basic and Translational Studies
- 636. Myelodysplastic Syndromes�Basic and Translational Studies
- 637. Myelodysplastic Syndromes�Clinical Studies: Personalized Clinical-Decision Tools and treatment of lower risk MDS
- 637. Myelodysplastic Syndromes�Clinical Studies: Treatment of Higher Risk Myelodysplastic syndromes
- 641. CLL: Biology and Pathophysiology, excluding Therapy: Genetic Models and Genomic Landscape of CLL and Richter Transformation
- 641. CLL: Biology and Pathophysiology, excluding Therapy: Treatment Resistance and Prognosis
- 642. CLL: Therapy, excluding Transplantation I
- 642. CLL: Therapy, excluding Transplantation II
- 651. Myeloma: Biology and Pathophysiology, excluding Therapy I
- 651. Myeloma: Biology and Pathophysiology, excluding Therapy II
- 651. Myeloma: Biology and Pathophysiology, excluding Therapy: From Smoldering Myeloma to Active Myeloma: Innovative Early Detection Approaches, Epigenetic, Genomic and Transcriptome Scenarios.
- 651. Myeloma: Biology and Pathophysiology, excluding Therapy: The Role of the Bone Marrow Microenvironment in the Pathogenesis and Therapy of Multiple Myeloma and Waldenstrom�s Macroglobulinemia.
- 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy
- 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Bispecific T Cell Engager Therapies and Novel Targeting Agents
- 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: CAR T Therapies for Myeloma: Novel Approaches and Longer-Term Follow Up Data
- 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Initial Therapy
- 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Novel Therapies Targeting B Cell Maturation Antigen in Relapsed/Refractory Multiple Myeloma
- 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation: Relapsed/Refractory Multiple Myeloma
- 653. Myeloma/Amyloidosis: Therapy, excluding Transplantation; Novel Approaches for Relapsed/Refractory Myeloma and Amyloidosis
- 701. Experimental Transplantation: Basic Biology, Pre-Clinical Models
- 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Adoptive Cell Therapy beyond CAR T cells
- 703. Adoptive Immunotherapy: Mechanisms and New Approaches: Optimizing CAR T cells for Improved Outcomes
- 704. Immunotherapies: Beyond T to NK
- 704. Immunotherapies: Therapeutic T cell Manipulation
- 711. Cell Collection and Processing
- 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities I
- 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Transplant Toxicities II
- 722. Clinical Allogeneic Transplantation: Acute and Chronic GvHD, Immune Reconstitution: Pathobiology and Predictive Biomarkers
- 722. Clinical Allogeneic Transplantation: Acute and Chronic GvHD, Immune Reconstitution: Phase I and II Trials
- 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence I
- 723. Clinical Allogeneic and Autologous Transplantation: Late Complications and Approaches to Disease Recurrence II
- 731. Clinical Autologous Transplantation: Autologous Transplantation: Still the Backbone of Modern Myeloma Therapies
- 731. Clinical Autologous Transplantation: Building Better Transplant Platforms in Lymphoid Malignancies
- 732. Clinical Allogeneic Transplantation Results II
- 732. Clinical Allogeneic Transplantation Results III
- 732. Clinical Allogeneic Transplantation: Results I
- 801. Gene Editing, Therapy and Transfer I
- 801. Gene Editing, Therapy and Transfer II
- 802. Chemical Biology and Experimental Therapeutics: Innovations in Therapy and Drug Screening
- 803. Emerging Diagnostic Tools and Techniques I
- 803. Emerging Diagnostic Tools and Techniques II
- 901. Health Services Research�Non-Malignant Conditions I
- 901. Health Services Research�Non-Malignant Conditions II
- 902. Health Services Research�Malignant Conditions (Lymphoid Disease) I
- 902. Health Services Research�Malignant Conditions (Lymphoid Disease) II
- 903. Health Services Research�Malignant Conditions (Myeloid Disease): Barriers to Cancer Care Delivery in Myeloid Malignancies
- 903. Health Services Research�Malignant Conditions (Myeloid Disease): Treatment and Publication Patterns in Myeloid Malignancies
- 904. Outcomes Research - Non-Malignant Conditions: Sickle Cell Disease and Beta Thalassemia
- 904. Outcomes Research - Non-Malignant Conditions: Venous Thromboembolism Associated with Cancer and/or COVID-19
- 904. Outcomes Research�Non-Malignant Conditions: Bleeding, Immune Thrombocytopenia, and Other Hematologic Disorders
- 905. Outcomes Research�Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Healthcare Disparities
- 905. Outcomes Research�Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Lymphoma
- 905. Outcomes Research�Malignant Conditions (Lymphoid Disease): Outcomes Research Real World Data Myeloma
- 906-Outcomes Research�Malignant Conditions (Myeloid Disease): Real World Management And Outcome
Scientific Program
- Challenges in Cell Therapy: Relapse and Toxicities
- Extrinsic Regulation of Hematopoietic Stem Cell Emergence and Homeostasis
- Getting the Most from Minimal Residual Disease
- Gut Microbiome and the Endothelium
- Hematopoietic Aging: Mechanisms and Consequences
- Location, Location, Location
- Mechanisms and Modifiers of Bleeding
- Molecular Basis of Platelet/Megakaryocyte Dysfunction: Novel Approaches
- Novel Blood Therapeutics
- Precision Medicine Approaches to Leukemia Predisposition in Bone Marrow Failure
- RNA in Normal and Malignant Hematopoiesis
- Single Cell Analysis of Hematopoietic Development and Clonal Complexity of Malignant Hematopoiesis
- The Immune System in Multiple Myeloma
- Well-Regulated vs Malfunctioning Mechanisms of Iron Metabolism
- What the Children Can Teach Us: Congenital Immunodeficiencies Shed Light on Immunity, Hematopoiesis, and Cancer
Special Scientific Symposia
Special-Interest Sessions
- ASH Choosing Wisely� Campaign: 2020 ASH Choosing Wisely Champions
- Blood & Beyond
- Modeling COVID-19: From the Lab to the World
- Special Scientific Session on Race and Science
- Special Symposium on Quality: Blood, Debt and Tears: Tackling Burnout in Hematology
- The 2020 Pandemic: Latest Insights on COVID-19
Spotlight Sessions
- Appropriate Use of Imaging in Patients with Lymphoma
- Cellular Breakups: Transfusion and Hyperhemolysis in Sickle Cell Disease
- Checkpoint Blockade: Defining A New Treatment Paradigm in Hodgkin Lymphoma and Allogeneic Transplantation
- Emicizumab�s Impact on the Landscape of Hemophilia A Treatment: Two Artists Debate the View
- How to Manage Common Challenging Situations in Patients with Multiple Myeloma
- Transfusion and Anemia in Global Health
- Vascular Anomalies 101: Case-Based Discussion on the Diagnosis, Treatment and Lifelong Care of These Patients
Trainee Activities and Services
ASH Meeting on Hematologic Malignancies
Hear the latest developments in clinical care, and get answers to your most challenging patient care questions.
Learn more
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
Copyright © 2021 by American Society of Hematology